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Abstract: A novel series of Mannich bases containing isoniazid were prepared. 
First, reaction of 2-propoxybenzaldehyde with isoniazid gave the correspond-
ing hydrazone (2a). Subsequently, product 2a after the Mannich reaction of 
aminomethylation with formaldehyde and secondary amines gave 2b–k. The 
inhibitory potencies of the synthesized compounds were assayed in vitro against 
a panel of microorganisms and against the A549 human lung adenocarcinoma 
cell line. Compounds 2c and 2k displayed moderate to potent antimicrobial 
activity against all the tested strains and they also exhibited significant cyto-
toxicity in a dose-dependent manner with IC50 values ranging from 2.84 to 8.55 
µg/mL and 0.007–0.030 mM. The structures of the newly synthesized com-
pounds were evaluated by elemental and spectral (IR, 1H-NMR,  13C-NMR) 
methods. The results demonstrated the potential and importance of developing 
new Mannich bases which would be effective against resistant microbial strains 
and may be useful leads for anticancer drug development in the future. 
Keywords: benzylidene; antimicrobial; cytotoxicity; Mannich bases; 1H-NMR; 
13C-NMR.  
INTRODUCTION 
The incidence of microbial infections has increased to startling levels world-
wide in the last 25 years because of antimicrobial resistance. The hasty develop-
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ment of resistance to existing antibacterial and antifungal drugs poses a major 
threat to public health and generates a serious challenge to the scientific commu-
nity. The increasing number of immuno-compromised patients as a result of can-
cer chemotherapy, organ transplantation and HIV infection are the major factors 
contributing to this increase. Consequently, there is a vital need for the develop-
ment of new antimicrobial agents having potent activity against the resistant mic-
roorganism.2–5 Hydrazones belong to the Schiff base family containing azome-
thine –NHN=CH– protons and the hydrazone moiety is considered one of the pri-
vileged structural fragments in modern medicinal chemistry due to its broad 
pharmacological vistas. Among the important pharmacophores responsible for 
antimicrobial activity, the hydrazone group is still considered a viable lead struc-
ture for the synthesis of more efficacious and broad-spectrum antimicrobial agents. 
Some widely used antibacterial drugs, such as nitrofurazone, furazolidone and 
ftivazide, contain the hydrazone group. Furthermore, pharmacokinetic and 
cellular permeability of a drug can be increased by derivatization to a biorever-
sible form of this drug, namely hydrazone. It is believed that the hydrazone 
functional group increases the lipophilicity of the parent amine and amides, 
which results in an enhancement of absorption through biomembranes and it is 
this enhanced lipophilicity of hydrazones which enables them to cross bacterial 
and fungal membranes.6,7 Hydrazones are formed when hydrazines react with an 
aldehyde or a ketone under specific condition. Hydrazones have been reported to 
possess antimicrobial,8,9 antitubercular,10,11 antileprotic,12 anticonvulsant,13 
analgesic,14 anti-inflammatory,15,16 antiplatelet,17 anticancer18,19 and antiviral 
properties.20 
Inspired by the above facts and in continuation of an ongoing research pro-
gram in the field of the synthesis and antimicrobial activity of medicinally impor-
tant compounds,21–24 the synthesis and antimicrobial activity of some novel deri-
vatives of isoniazid are reported herein. 
EXPERIMENTAL 
Melting points of the synthesized compounds were determined in open-glass capillaries 
on a Stuart SMP10 melting point apparatus and are uncorrected. The purity of the compounds 
was checked by thin layer chromatography (TLC). Silica gel plates 0.25 mm, 60 GF254, pre-
coated sheets, obtained from Merck, Darmstadt (Germany), were used for the TLC and the 
spots were visualized by iodine vapor or ultraviolet light as visualizing agents. The infrared 
(IR) spectra were obtained on a Perkin-Elmer 1600 FTIR spectrometer in KBr pellets. The 
nuclear magnetic resonance (NMR) spectra were recorded in deuterated dimethyl sulfoxide 
(DMSO-d6) solutions using tetramethylsilane as the internal reference. A Varian-Mercury 300 
MHz spectrometer was used for recording the 1H-NMR spectra while the 13C-NMR spectra 
were acquired on a Bruker Avance II 400 spectrometer. Elemental analyses were performed 
on an ECS 4010 elemental combustion system. The necessary chemicals were purchased from 
Loba Chemie, Fluka and Sigma-Aldrich. 
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Synthesis of 2-propoxybenzylideneisonicotinohydrazide. 
A mixture of 2-propoxybenzaldehyde (1.64 g, 0.010 mol) and isoniazid (1.37 g, 0.010 
mol) in 15 ml of super dry ethanol was refluxed for 5 h. Completion of the reaction was 
confirmed by thin layer chromatography (TLC). The reaction mixture was then poured into 
ice-cold water and the obtained precipitate was filtered and dried in oven at a low temperature. 
The product was recrystallized from absolute ethanol.  
Synthesis of substituted Mannich bases (2b–k) 
2-Propoxybenzylideneisonicotinohydrazide (1) (679 mg, 0.0024 mol), formaldehyde 
(0.10 ml, 0.0036 mol) and the required substituted secondary amine (0.0024 mol) were placed 
in 100 ml round-bottom flask to which 50 ml of super dry ethanol was added, the pH was 
adjusted to 4 with hydrochloric acid and the mixture was refluxed for 28–33 h. Completion of 
the reaction was confirmed by TLC. The reaction mixture was allowed to cool to room tem-
perature and then diethyl ether was added. The reaction mixture was kept for 3–5 h in a 
refrigerator. The resulting solid was filtered off and washed with n-hexane. The products were 
recrystallized from absolute ethanol.  
Antimicrobial evaluation 
The synthesized compounds were evaluated for their in vitro antimicrobial activity 
against the Gram-positive bacteria Staphylococcus aureus (MTCC 96), Bacillus subtilis 
(MTCC 121), Gram-negative Escherichia coli (MTCC 40), Pseudomonas aeruginosa (MTCC 
2453) and the fungal strains Candida albicans (MTCC 227) and Aspergillus niger (MTCC 
8189). The antimicrobial activity was assessed by the serial two-fold dilution technique. 
Amoxicillin was used as the standard drug for the antibacterial activity and nystatin was used 
as the standard drug for the antifungal activity. All the compounds were dissolved in dimethyl 
sulfoxide (DMSO) to give a concentration of 100 µg mL-1. Twofold dilutions of the test and 
standard compounds were prepared in double strength nutrient broth for bacteria (Indian 
Pharmacopoeia: peptone 10 g, meat extracts 10 g, sodium chloride 0.5 g, distilled water 1000 
mL, and pH 7.2±0.2) or Sabouraud dextrose broth for fungi (Indian Pharmacopoeia)25. The 
stock solutions were serially diluted to give concentrations of 50–0.78 µg mL-1 in the res-
pective nutrient broth. The inoculum size was approximately 106 colony forming units (CFU) 
mL-1. The tubes were incubated at 37±1 °C for 24 h (bacteria) and 25 °C for 7 d (A. niger) 
and 37±1 °C for 48 h (C. albicans). After incubation, the inoculated culture tubes were 
macroscopically examined for turbidity. The culture tube showing turbidity (lower concen-
tration) and the culture tube showing no turbidity (higher concentration) gave the minimum 
inhibitory concentration (MIC) for the compound. 
Cytotoxicity studies 
The A549 (human lung adenocarcinoma) cell line was obtained from the National Centre 
for Cell Science, Pune, India. The cells were grown in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 2 mmol L-1 L-glutamine, 10 % fetal bovine serum (FBS), peni-
cillin (50 IU mL-1) and streptomycin (50 mg mL-1) at a temperature of 37 °C in a humidified 
incubator with a 5 % CO2 atmosphere. Gemcitabine, a well known anticancer drug, was used 
as the positive control for comparison.26 The viability of the cells was assessed by the MTT 
2-(5-dimethylthiazol-2-yl)-3,5-diphenyl-2H-tetrazolium bromide) assay, which is based on the 
reduction of MTT by the mitochondrial dehydrogenase of intact cells to a purple formazan 
product.27 Cells (1×104) were placed in a 96-well plate. After 24 h, they were treated with 
different concentrations (0–25 µg/mL) of the test compounds diluted appropriately with cul-
ture media for 48 h. Cells grown in media containing an equivalent amount of DMSO served 
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as the positive control and cells in medium without any supplementation were used as the 
negative control. After the treatment, the media containing the compounds were carefully 
removed. MTT in phosphate-buffered saline (PBS, 100 μL, 0.40 mg mL-1) was added to each 
well and incubated in the dark for 4 h. Then DMSO (100 μL) was added to each well and kept 
in an incubator for 4 h for dissolution of the formed formazan crystals. The amount of 
formazan was determined by measuring the absorbance at 540 nm using an ELISA plate 
reader. The data are presented as percent post treatment recovery (% of live cells), whereas the 
absorbance from non-treated control cells was defined as 100 % live cells. 
RESULT AND DISCUSSION 
The synthesis of target compounds were carried as outlined in the Scheme 1. 
An equimolar quantity of 2-propoxybenzaldehyde and isoniazid in 15 ml of abso-
lute ethanol was refluxed for 7 h to form acid hydrazone. The completion of reac-
tion was confirmed by thin layer chromatography (TLC). Then 2-propoxybenzyl-
ideneisonicotinohydrazide along with formaldehyde and secondary amines was 
refluxed for 34–42 h in presence of 50 ml of super dry ethanol and the pH was 
adjusted to 4 with hydrochloric acid. The employed secondary amines are 
specified in Table I. 
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Scheme 1. General synthetic pathway for the formation of the title compounds. 
The purity of the compounds was checked by TLC and they were characte-
rized by elemental analysis and IR, 1H- and 13C-NMR spectroscopy. The results 
of the elemental analyses and the spectral data are given in the Supplementary 
data to this paper. 
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In general, the IR spectra of all compounds 2a–k showed absorption band in 
the 3279–3255, 2978–2946, 2862–2835, 1677–1663, 1659–1641, 1581–1552, 
1174–1125 and 1079–1038 cm–1 regions, conforming the presence of NH, CH, 
CH2, C=N, C=O, C=C and C–N, respectively. The structures of the prepared de-
rivatives were confirmed by their 1H-NMR spectrum based on the chemical shifts, 
multiplicities, and coupling constants. The spectra of most compounds showed 
the characteristic NH proton at δ 11.98–11.79 ppm, the proton of –N=C–H at δ 
8.79–8.21 ppm, the 4 protons of pyridine at around δ 8.86–7.46 ppm, the cha-
racteristic protons of benzylidene at δ 7.77–6.78 ppm, the 2 protons of Ar–O– 
–CH2 at δ 3.94–3.62 ppm and the 2 protons of Ar–CH2–N at δ 3.69–3.49 ppm, 
The 13C-NMR spectra of most compounds had characteristic signals of C=O at 
around δ 163.91–163.18 ppm, of pyridine at δ 149.88–122.15 ppm, of the –N=C–H 
group at δ 143.48–143.19 ppm, of benzylidene at δ 157.58–115.75 ppm and of 
Ar–O–CH2 at δ 72.84–72.19 ppm and Ar–CH2–N at δ 55.89–45.59 ppm. 
TABLE I. Structure and physical data of the synthesized Mannich bases 
N C
O
NH N C
H
OR
CH3
 
Compound  R  Molecular formulae  Yield, %  M.p., °C 
2b  –N(CH3)2  C19H24N2O2 48 227–230 
2c  –N(C2H5)2 C 21H28N4O2 45 235–238 
2d  –N(C3H7)2 C 23H32N4O2 52 212–215 
2e  –N(C4H9)2 C 25H36N4O2 43 218–221 
2f  –N(C6H5)2 C 29H28N4O2 39 182–185 
2g 
N
C22H28N4O2  48 188–191 
2h 
N
C21H26N4O2  45 193–196 
2i 
NO
C21H26N4O3 40  223–226 
2j 
NN H
C21H27N5O2  43 205–208 
2k 
NN C H 3
C22H29N5O2  46 117–120 
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The compounds were evaluated for their antimicrobial properties in compa-
rison the control antibacterial agent amoxicillin and antifungal agent nystatin.  
The results of antibacterial screening, Table II, revealed that all the tested 
compounds showed moderate to good bacterial inhibition. Compounds 2c and 2k 
displayed excellent activity against the microbial strains. Compounds 2d, 2h, 2i 
and 2j showed moderate antibacterial activity. Of all the synthesized derivatives, 
compound 2a was found to be the least active compound against most of bacte-
rial strains. Concerning the antifungal activity of the tested compounds, only two 
fungal strains were selected, C. albicans and A. niger. The data of the antifungal 
screening, Table II, revealed that all the tested compounds showed moderate to 
good fungal inhibition as compared to standard drug nystatin. Among the deriva-
tives, compound 2c exhibited the highest antifungal activity against both fungal 
strains, while compounds 2e, 2g and 2j showed moderate antifungal activity. Of 
all the synthesized derivatives, compound 2b was found to be the least active 
compound against both fungal strains. 
In addition, all the tested compounds demonstrated remarkable cytotoxicity 
against A549 lung cancer cell line, Table III. In particular, compounds 2c and 2k 
displayed significant inhibitory activity superior to that of the reference com-
pound gemcitabine. 
TABLE II. Antimicrobial screening results (MIC / µg mL-1) of the tested compounds 
Compound 
Gram-positive bacteria  Gram-negative bacteria  Fungal strain 
B. subtilis   S. aureus  P. aeruginosa  E. coli  C. albicans  A. nigar 
2a  25 12.5  12.5  6.25 25  12.5 
2b  6.25 12.5  3.12  6.25  25  >100 
2c  0.78 1.56  1.56  3.12 1.56  3.12 
2d  3.12 12.5  6.25  25  12.5  12.5 
2e  25 >100  12.5  6.25  3.12  12.5 
2f  12.5 6.25  12.5  12.5 6.25  >100 
2g  12.5 25  25  12.5  12.5  6.25 
2h  6.25 25  12.5  6.25  12.5  25 
2i  6.25 6.25  12.5  12.5 12.5  3.12 
2j  6.25 12.5  6.25  12.5 12.5  6.25 
2k  3.12 6.25  1.56  1.56 12.5  25 
Amoxicillin 0.15  0.15 0.25 0.15 – – 
Nystatin  –  – – – 0.25 0.78 
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TABLE III. The cytotoxicity data against the A549 lung cancer cell line of the synthesized 
compounds 
Compound 
Cell death at various doses (in µg/mL), %  IC50
a 
µg mL-1 
IC50 
mM  1 2 5  10  25 
2a  3.13  17.55 30.85 47.62 60.81  8.55  0.030 
2b  4.19  18.13  31.18 48 61.28 8.12  0.023 
2c  10.54 30.73 41.18 73.48 77.29  2.84  0.007 
2d  9.12  23.26 36.55 69.84 71.39  4.18  0.010 
2e  5.83  19.63 32.15 60.45 65.64  6.58  0.015 
2f  4.15  18.25 31.52 51.13 62.81  7.73  0.016 
2g  4.85  18.33 31.87 55.18 64.35  7.15  0.018 
2h  9.15  21.35 34.16 66.65 70.19  5.18  0.014 
2i  8.87  20.17 32.55 63.72 69.39  5.92  0.015 
2j  8.22  19.77 32.12 61.15 66.29  6.29  0.016 
2k  9.53  25.23 39.19 71.19 74.11  3.36  0.008 
Gemcitabine  6.53  15.18 25.93 54.58 71.18  6.19  0.023 
aThe half maximal (50%) inhibitory concentration (IC) of a substance 
CONCLUSIONS 
In conclusion, the present paper describes the preparation and biological eva-
luation of a series of novel isoniazid derivatives. The synthesized compounds 
were characterized by suitable analytical techniques, i.e., IR, 1H-NMR, 13C-NMR 
and elemental analysis and the data obtained was in full agreement of the pro-
posed structures. Among the synthesized derivatives, compound 2c and 2k, having 
a diethylamino and methylpiperazine moieties, were the most active compounds 
with significant biological activity. Based on preliminary antimicrobial and cyto-
toxicity results, it is supposed that both these compounds display antimicrobial 
and cytotoxicity activities through a non-specific mechanism of action or that they 
exert antimicrobial action due to their cytotoxicity activity. Taken together, the 
compounds reported in this paper could serve as potential leads for future studies 
and that further investigations are warranted to determine the mechanism of ac-
tion of these molecules. 
SUPPLEMENTARY MATERIAL 
Аnalytical and spectral data of synthesized compounds are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
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ДЕРИВАТА 2-ПРОПОКСИБЕНЗИЛИДЕН-ИЗОНИКОТИНОХИДРАЗИДА  
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Синтетисана је серија нових Манихових база, деривата изонијазида. Прво је реакцијом 
2-пропоксибензалдехида са изонијазидом добијен одговарајући хидразон (2а). Производ 2а 
је у Маниховој реакцији аминометиловања формалдехидом и секундарним аминима дао про-
изводе (2b–k). Инхибиторна in vitro активност добијених једињења испитана је према панелу 
микроорганизама и А549 ћелијској линији аденокарцинома плућа. Деривати 2c и 2k имају 
умерену активност према микроорганизмима, и показују значајну цитотоксичност која за-
виси од примењене концентрације једињења. IC50 вредности налазе се у опсегу 2,84–8,55 
µg/mL и 0,007–0,030 mM. Структуре синтетисаних једињења одређене су на основу резул-
тата елементалне анализе и спектралних података (IC, 1H-NMR и 13C-NMR). Добијени ре-
зултати показују на значај развоја Манихових база, које могу бити активне према резистент-
ним сојевима микроорганизама, и могу бити развијани као успешни модели за развој анти-
туморских једињења. 
(Примљено 10. марта, ревидирано 18. јуна 2011) 
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